Changes in Medical Management after Coronary CT Angiography

• Main Authors: Vânia Mairi Naue, Gabriel Camargo, Letícia Roberto Sabioni, Ronaldo de Souza Leão Lima, Maria Eduarda Derenne, Andréa Rocha de Lorenzo, Monica Di Calafiori Freire, Clério Francisco Azevedo Filho, Elmiro Santos Resende, Ilan Gottlieb
• Format: Article
• Language: English
• Published: Sociedade Brasileira de Cardiologia (SBC) 2015-01-01
• Series: Arquivos Brasileiros de Cardiologia
• Subjects: Doença arterial coronariana; Diagnóstico por Imagem; Terapêutica; Aterosclerose/fisiopatologia
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015005050088&lng=en&tlng=en

Abstract Introduction: Coronary computed tomography angiography (CCTA) allows for non-invasive coronary artery disease (CAD) phenotyping. There are still some uncertainties regarding the impact this knowledge has on the clinical care of patients. Objective: To determine whether CAD phenotyping by CCTA influences clinical decision making by the prescription of cardiovascular drugs and their impact on non-LDL cholesterol (NLDLC) levels. Methods: We analysed consecutive patients from 2008 to 2011 submitted to CCTA without previous diagnosis of CAD that had two serial measures of NLDLC, one up to 3 months before CCTA and the second from 3 to 6 months after. Results: A total of 97 patients were included, of which 69% were men, mean age 64 ± 12 years. CCTA revealed that 18 (18%) patients had no CAD, 38 (39%) had non-obstructive (< 50%) lesions and 41 (42%) had at least one obstructive ≥ 50% lesion. NLDLC was similar at baseline between the grups (138 ± 52 mg/dL vs. 135 ± 42 mg/dL vs. 131 ± 44 mg/dL, respectively, p = 0.32). We found significative reduction in NLDLC among patients with obstrctive lesions (-18%, p = 0.001). We also found a positive relationship between clinical treatment intensification with aspirin and cholesterol reducing drugs and the severity of CAD. Conclusion: Our data suggest that CCTA results were used for cardiovascular clinical treatment titration, with especial intensification seen in patients with obstructive ≥50% CAD.